European Clinical Laboratory Services Growth Opportunity

European Clinical Laboratory Services Growth Opportunity

Customer Experience Driven by New B2B and B2C Business Models

RELEASE DATE
01-Mar-2022
REGION
Europe
Research Code: K720-01-00-00-00
SKU: HC03514-EU-MT_26320
$2,450.00
In stock
SKU
HC03514-EU-MT_26320
$2,450.00
DownloadLink

Pay by invoice

ENQUIRE NOW

Description

Diagnostics is the backbone of the healthcare sector. According to a World Health Organization (WHO) study, although the segment accounts for less than 5% of hospital costs, its findings influence 60–70% of healthcare decision-making. Diagnostics helps to analyze medical conditions and guide patients toward the right medication, treatment, or surgery. The COVID-19 pandemic has underscored and redefined the significance of clinical laboratories. Working largely unseen, laboratories are a vital link in the chain of activities required to keep populations safe from diseases. In recognition of this, the WHO and the European Centre for Disease Prevention and Control (ECDC) moved quickly following the identification of the virus on 7 January 2020 to identify laboratory needs and capacities in Europe.

Molecular testing stepped up to meet the additional demand for insights in diagnostics, life science research, pharmaceutical R&D, and public safety. Molecular diagnostics is expanding to new areas of medicine and is enabling clinicians to monitor cancer, infectious disease, immune status, and pre-natal and neo-natal health. The migration of genomic technologies from basic research into the mainstream will remain a powerful driver for long-term industry growth and will boost the need for scalable and efficient user-friendly workflows in molecular testing.

Labs will have to provide comprehensive IVD solutions and cover clinical chemistry and immunoassays, molecular and digital diagnostics, POCT, patient self-testing, next-generation sequencing, laboratory automation and IT, and decision support, where half or more of the population has private coverage. Value-based healthcare (VBHC) is increasingly used in public discourse and, often, value is discussed as health outcomes relative to the monetized input. No singular definition of value exists in the VBHC space; the definition is subjective, and what is considered valuable can differ across patients, clinicians, healthcare providers, policymakers, and industry stakeholders.

Author: Tejashri Khadilkar

RESEARCH: INFOGRAPHIC

This infographic presents a brief overview of the research, and highlights the key topics discussed in it.
Click image to view it in full size

Table of Contents

Why Is It Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top Three Strategic Imperatives on the European Clinical Laboratory Services Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Market Segmentation

Opportunity and Threat Analysis

Opportunity and Threat Analysis (continued)

Key Trends

Key Trends (continued)

Key Trends (continued)

Growth Drivers

Growth Drivers (continued)

Growth Drivers (continued)

Growth Restraints

Growth Restraints (continued)

Growth Restraints (continued)

Market Highlights

COVID-19 Impact on Clinical Testing Services and Healthcare Diagnostics

European Clinical Laboratory Services Market—Highlights

EU5 Clinical Laboratory Services Market—Highlights

EU5 Clinical Laboratory Services Market—Highlights (continued)

European Clinical Laboratory Services Market—Highlights

Competitor Landscape*

Labcorp (Independent Reference Laboratory)

Quest Diagnostics (Independent Reference Laboratory)

Sonic Healthcare (Independent Reference Laboratory)

Eurofins Scientific (Independent Reference Laboratory)

Synlab International GmbH (Independent Reference Laboratory)

Myriad Genetics, Inc. (Independent Speciality Laboratory)

Centogene—The Rare Disease Company (Independent Speciality Laboratory)

Freiburg University Hospital (Hospital-based Laboratory)

Medicover Hospital (Hospital-based Laboratory)

Holistic Business Model—Laboratories as One-stop Shop Service Providers

Cross-sectoral Partnerships

Growth Opportunity 1—Increased Support for Europe’s Beating Cancer Plan for Improved Early Detection, Treatment, and Care

Growth Opportunity 1—Increased Support for Europe’s Beating Cancer Plan for Improved Early Detection, Treatment, and Care (continued)

Growth Opportunity 2—On-demand Digital Diagnostic Services for Improved Access and Personalized Healthcare

Growth Opportunity 2—On-demand Digital Diagnostic Services for Improved Access and Personalized Healthcare (continued)

Growth Opportunity 3—Advance Diagnostic Excellence for a Superior Patient and Clinician Experience

Growth Opportunity 3—Advance Diagnostic Excellence for a Superior Patient and Clinician Experience (continued)

Growth Opportunity 4—Transition to AI and Digital Pathology for Efficient Multisite Operations

Growth Opportunity 4—Transition to AI and Digital Pathology for Efficient Multisite Operations (continued)

Conclusions

Bibliography

Bibliography (continued)

List of Exhibits

Legal Disclaimer

Diagnostics is the backbone of the healthcare sector. According to a World Health Organization (WHO) study, although the segment accounts for less than 5% of hospital costs, its findings influence 60–70% of healthcare decision-making. Diagnostics helps to analyze medical conditions and guide patients toward the right medication, treatment, or surgery. The COVID-19 pandemic has underscored and redefined the significance of clinical laboratories. Working largely unseen, laboratories are a vital link in the chain of activities required to keep populations safe from diseases. In recognition of this, the WHO and the European Centre for Disease Prevention and Control (ECDC) moved quickly following the identification of the virus on 7 January 2020 to identify laboratory needs and capacities in Europe. Molecular testing stepped up to meet the additional demand for insights in diagnostics, life science research, pharmaceutical R&D, and public safety. Molecular diagnostics is expanding to new areas of medicine and is enabling clinicians to monitor cancer, infectious disease, immune status, and pre-natal and neo-natal health. The migration of genomic technologies from basic research into the mainstream will remain a powerful driver for long-term industry growth and will boost the need for scalable and efficient user-friendly workflows in molecular testing. Labs will have to provide comprehensive IVD solutions and cover clinical chemistry and immunoassays, molecular and digital diagnostics, POCT, patient self-testing, next-generation sequencing, laboratory automation and IT, and decision support, where half or more of the population has private coverage. Value-based healthcare (VBHC) is increasingly used in public discourse and, often, value is discussed as health outcomes relative to the monetized input. No singular definition of value exists in the VBHC space; the definition is subjective, and what is considered valuable can differ across patients, clinicians, healthcare providers, policymakers, and industry stakeholders. Author: Tejashri Khadilkar
More Information
No Index No
Podcast No
Author Tejashri Manish Khadilkar
Industries Healthcare
WIP Number K720-01-00-00-00
Is Prebook No
GPS Codes 9600-B1,9573-B1,9627-B1